AR121038A1 - GLUCOSE-SENSITIVE INSULIN DERIVATIVES - Google Patents

GLUCOSE-SENSITIVE INSULIN DERIVATIVES

Info

Publication number
AR121038A1
AR121038A1 ARP200100873A ARP200100873A AR121038A1 AR 121038 A1 AR121038 A1 AR 121038A1 AR P200100873 A ARP200100873 A AR P200100873A AR P200100873 A ARP200100873 A AR P200100873A AR 121038 A1 AR121038 A1 AR 121038A1
Authority
AR
Argentina
Prior art keywords
insulin derivatives
glucose
sensitive insulin
diabetes
prevention
Prior art date
Application number
ARP200100873A
Other languages
Spanish (es)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR121038A1 publication Critical patent/AR121038A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a derivados de insulina y su uso en el tratamiento o prevención de afecciones médicas relacionadas con la diabetes. Los derivados de insulina son sensibles a la glucosa y presentan una unión a albúmina sensible a glucosa. La presente también se refiere a productos intermedios. Finalmente, la presente proporciona una composición farmacéutica que comprende los derivados de insulina de la presente y el uso de tal composición en el tratamiento o prevención de afecciones médicas relacionadas con la diabetes.This relates to insulin derivatives and their use in the treatment or prevention of medical conditions related to diabetes. Insulin derivatives are glucose sensitive and exhibit glucose sensitive albumin binding. This also refers to intermediate products. Finally, the present provides a pharmaceutical composition comprising the insulin derivatives herein and the use of such a composition in the treatment or prevention of medical conditions related to diabetes.

ARP200100873A 2019-03-29 2020-03-27 GLUCOSE-SENSITIVE INSULIN DERIVATIVES AR121038A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19166131 2019-03-29

Publications (1)

Publication Number Publication Date
AR121038A1 true AR121038A1 (en) 2022-04-13

Family

ID=66041185

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100873A AR121038A1 (en) 2019-03-29 2020-03-27 GLUCOSE-SENSITIVE INSULIN DERIVATIVES

Country Status (1)

Country Link
AR (1) AR121038A1 (en)

Similar Documents

Publication Publication Date Title
CO2021013251A2 (en) Glucose-sensitive insulin derivatives
CY1119582T1 (en) HYDRAULIC INSULIN PREPARATIONS CONTAINING Methionine
CY1114703T1 (en) PHARMACEUTICAL COMPOSITION OF INCLUSIVE (1S) -1,5-ANHYRO-1- [5- (4-Ethoxybenzyl) -2-Methoxy-4-Methylphenyl] -1-Sulfuryl
BR112015019430A2 (en) wound-forming film-forming pharmaceutical composition and method for its preparation
UY29020A1 (en) SALICILTIAZOLES REPLACED WITH DIFENYLAMINE OR DERIVATIVES OF DIFENYLAMINE, PROCEDURES FOR PREPARATION AND USE.-
DOP2010000408A (en) CHEMICAL COMPOUNDS 251
AR059982A1 (en) TUMOR THERAPY WITH AN ANTIBODY AGAINST THE VASCULAR ENDOTELIAL GROWTH FACTOR AND AN ANTIBODY AGAINST THE HUMAN TYPE 2 EPITELIAL GROWTH FACTOR RECEIVER
CY1117603T1 (en) LIXISENATIDE AS AN ADDITION TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES
DOP2011000264A (en) AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
CL2009000757A1 (en) Compounds derived from 6,8,2'-tris- (isobut-2-en-1-yl) -diosmethine; procedures for its preparation; pharmaceutical composition comprising them; and its use in the treatment of chronic venous diseases, post-thrombotic syndrome, vascular complications linked to diabetes, among others.
BR112013024973A2 (en) prevention of hypoglycemia in patients with type 2 diabetes mellitus
CY1119850T1 (en) USE OF METFORMIN IN COMBINATION WITH AN INTERACTIVE GLYKINASE AND COMPOSITIONS INCLUDING METFORMIN AND ACTIVATOR
BR112018003817A2 (en) surgical aids with medications affected by activators
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
UY30158A1 (en) USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR PAIN TREATMENT
CL2008002356A1 (en) Piperazine-amide sulfoxides; its preparation processes; the pharmaceutical compositions containing them; and its use in the treatment of diseases that are modulated with lxr alpha and / or beta agonists.
AR035651A1 (en) USE OF INDOL DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO REDUCE INTRAOCULAR PRESSURE AND A COMPOSITION
PE20191836A1 (en) ACILLATED INSULIN COMPOUND
CL2023000087A1 (en) Glp-1 and gip receptor coagonists suitable for oral delivery
MX2022006742A (en) Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives.
UY29846A1 (en) N- (1,3,4) -TIADIAZOL-2-IL-BENCENSULPHONAMIDES, PROCESSES FOR PREPARATION AND USE AS PHARMACEUTICAL PRODUCTS
CY1116303T1 (en) ACYLVENZOLI PRODUCER
AR107560A1 (en) COMPOUND THAT DECREASES GLUCOSE IN BLOOD
CU23701A1 (en) METHOD OF TREATMENT OF INTESTINAL INFLAMMATORY DISEASES AND TYPE I DIABETES
AR121038A1 (en) GLUCOSE-SENSITIVE INSULIN DERIVATIVES

Legal Events

Date Code Title Description
FB Suspension of granting procedure